The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).
 
Deepa Jagadeesh
Consulting or Advisory Role - AFM; Daiichi Sankyo/Lilly; Genmab
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Debiopharm Group (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Merck (Inst); Regeneron (Inst); Rhizen Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Michal Taszner
Consulting or Advisory Role - BeiGene; Roche
Speakers' Bureau - BeiGene; Roche; Takeda
Travel, Accommodations, Expenses - SOBI; Takeda
 
Geoffrey Chong
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Regeneron (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dizal Pharma (Inst); Dizal Pharma (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Innate Pharma (Inst); Isofol Medical (Inst); Merck Serono (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst)
 
Silvana Novelli
No Relationships to Disclose
 
Seok-Goo Cho
No Relationships to Disclose
 
Jose Villasboas
Consulting or Advisory Role - Curio Science (Inst); Kite/Gilead (Inst); Regeneron (Inst); TG Therapeutics (Inst)
Research Funding - Aptose Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Enterome (Inst); Epizyme (Inst); Genentech/Roche (Inst); Regeneron (Inst)
 
Michele Merli
Consulting or Advisory Role - Lilly; Regeneron
 
Ana Ubieto
No Relationships to Disclose
 
Benoît Tessoulin
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Incyte; Kite, a Gilead Company
Research Funding - Abbvie
Travel, Accommodations, Expenses - Abbvie; Kite, a Gilead Company; Roche
 
Michelle Poon
Consulting or Advisory Role - Beigene; Regeneron
Speakers' Bureau - Regeneron
Research Funding - Genmab; Regeneron
 
David Tucker
Consulting or Advisory Role - Abbvie; Beigene; Regeneron; Roche
Speakers' Bureau - Abbvie
 
Jan Walewski
Honoraria - Gilead Sciences; Roche
Consulting or Advisory Role - Gilead Sciences; MSD Oncology; Regeneron
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Epizyme; European Mantle Cell Lymphoma Network; Gilead Sciences; Incyte; Janssen-Cilag; Karyopharm Therapeutics; Loxo/Lilly; MorphoSys; MSD Oncology; Polih Myeloma Consortium; Regeneron; Seagen; Takeda; TG Therapeutics
 
Shuhua Yi
No Relationships to Disclose
 
Jingxian Cai
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Jurriaan Brouwer-Visser
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Aafia Chaudhry
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Hesham Mohamed
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Odronextamab related patents
 
Srikanth Ambati
Employment - Regeneron Pharmaceuticals, Inc. (at the time of study)
Stock and Other Ownership Interests - Regeneron Pharmaceuticals, Inc. (at the time of study)
Patents, Royalties, Other Intellectual Property - Regeneron Pharmaceuticals, Inc. (at the time of study)
Travel, Accommodations, Expenses - Regeneron Pharmaceuticals, Inc. (at the time of study)
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Chong Kun Dang Pharmaceutical; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Merck KGaA; Novartis; Regeneron; Roche; Samsung Bioepis; Takeda
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Yuhan (Inst)